L3VLUP
ProSign in

GMED · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GMEDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GMED
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterGMEDVRTX
Q3 20208 holders, $639m31 holders, $21.9bn
Q4 20206 holders, $855m30 holders, $18.4bn
Q1 20217 holders, $779m31 holders, $15.4bn
Q2 202110 holders, $997m30 holders, $12.7bn
Q3 20219 holders, $871m35 holders, $10.1bn
Q4 202110 holders, $912m28 holders, $12.4bn
Q1 202210 holders, $934m23 holders, $16.1bn
Q2 20227 holders, $684m25 holders, $18.1bn
Q3 20226 holders, $781m22 holders, $18.4bn
Q4 20226 holders, $840m28 holders, $18.4bn
Q1 202315 holders, $720m26 holders, $21.4bn
Q2 202321 holders, $946m27 holders, $24.7bn
Q3 202317 holders, $881m33 holders, $24.3bn
Q4 202312 holders, $912m32 holders, $28.6bn
Q1 20248 holders, $772m31 holders, $29.8bn
Q2 202413 holders, $1.0bn29 holders, $33.4bn
Q3 202412 holders, $868m27 holders, $33.5bn
Q4 202414 holders, $1.4bn26 holders, $28.5bn
Q1 202513 holders, $951m21 holders, $35.4bn
Q2 202512 holders, $897m21 holders, $32.3bn
Q3 202511 holders, $765m22 holders, $25.9bn
Q4 202513 holders, $1.6bn26 holders, $31.8bn
Q1 202614 holders, $1.6bn25 holders, $31.8bn
Q2 202610 holders, $1.1bn26 holders, $34.6bn
GMED

Globus Medical Inc

Holders
12
Reported value
$912m
Buyers
5
Sellers
7

Breadth -2 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GMED (4)

Baillie Gifford & Co, GAMCO Investors Inc, Holocene Advisors LP, Quantbot Technologies LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Maverick Capital Ltd, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Voloridge Investment Management LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →